Molfetta and colleagues reported that CD112 undergoes proteolysis through ubiquitination and that inhibition of the ubiquitin pathway increases its cell-surface expression, which enhances the efficacy of NK cells in killing tumor cells.106 TRC8 is the RING E3 ligase that recognizes CD112 as a substrate.107. The gene discussed is NECTIN2; the disease is neoplasm.